Ana Maria Arance Fernandez, MD, PhD, of the Hospital Clínic de Barcelona, discusses the negative results of the phase III IMspire170 trial, which evaluated cobimetinib/atezolizumab vs pembrolizumab monotherapy in patients with BRAF V600 wild-type melanoma (Abstract LBA69).
Mansoor R. Mirza, MD, of Copenhagen University Hospital, and Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings, wh...
Laura Q.M. Chow, MD, of the University of Texas at Austin, Dell Medical School and LIVESTRONG Cancer Institutes, discusses phase II study findings that showe...
Angela Lamarca, MD, PhD, of the Christie NHS Foundation Trust, discusses findings from a study that showed new staging criteria should be considered for patients diagnosed wi...
Isabelle Laure Ray-Coquard, MD, PhD, of the Centre Leon Bérard, discusses phase III study findings in patients with newly diagnosed, advanced ovarian cancer who received olap...
Aleix Prat, MD, PhD, of Hospital Clinic de Barcelona, discusses the findings of a meta-analysis showing that the HER2-E subtype may predict pathologic complete response beyon...